{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:13:35Z","timestamp":1787501615278,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171309"],"award-info":[{"award-number":["82171309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52450010"],"award-info":[{"award-number":["52450010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012462","name":"Collaborative Innovation Center of Suzhou Nano Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20240040"],"award-info":[{"award-number":["BK20240040"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jconrel.2025.114168","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:53:08Z","timestamp":1756137188000},"page":"114168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["In situ formed chemo-immunotherapeutic hydrogel for suppression of postoperative glioma recurrence and intraoperative hemostasis"],"prefix":"10.1016","volume":"387","author":[{"given":"Jiahao","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114168_bb0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2025.114168_bb0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2025.114168_bb0015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.114168_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/neuonc\/not229","article-title":"Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop","volume":"16","author":"Huse","year":"2014","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2025.114168_bb0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrc2818","article-title":"Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma","volume":"10","author":"Huse","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114168_bb0030","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1200\/JCO.22.02772","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"41","author":"Friedman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines(R) insights: central nervous system cancers, Version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jconrel.2025.114168_bb0040","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.114168_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.114168_bb0050","article-title":"Advancements and challenges in brain cancer therapeutics","volume":"4","author":"Bai","year":"2024","journal-title":"Exploration (Beijing)"},{"key":"10.1016\/j.jconrel.2025.114168_bb0055","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.114168_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-024-02973-5","article-title":"From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review","volume":"43","author":"Regmi","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114168_bb0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/17512433.2020.1817737","article-title":"Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook","volume":"13","author":"Gedeon","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2025.114168_bb0075","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114168_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tips.2019.12.003","article-title":"Immunotherapy for malignant glioma: current status and future directions","volume":"41","author":"Wang","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2025.114168_bb0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114168_bb0090","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1084\/jem.20080099","article-title":"Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma","volume":"205","author":"Quezada","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2025.114168_bb0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1alpha in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0100","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41418-022-00969-2","article-title":"Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation","volume":"29","author":"Liu","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2025.114168_bb0105","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1038\/s41388-021-01846-x","article-title":"Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy","volume":"40","author":"Lequeux","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.114168_bb0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.114168_bb0115","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156774","article-title":"HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy","volume":"132","author":"Salman","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.114168_bb0120","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s12272-011-1021-3","article-title":"A novel approach to cancer therapy using PX-478 as a HIF-1alpha inhibitor","volume":"34","author":"Lee","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.114168_bb0125","first-page":"1198","article-title":"Inhibition of HIF-1alpha by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114168_bb0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114168_bb0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2016.00256","article-title":"Immunotherapy of malignant tumors in the brain: how different from other sites?","volume":"6","author":"Dutoit","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jconrel.2021.06.001","article-title":"A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief","volume":"335","author":"Jiang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114168_bb0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1535-7163.233.3.3","article-title":"Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha","volume":"3","author":"Welsh","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2025.114168_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.108104","article-title":"Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy","volume":"34","author":"Zhai","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2025.114168_bb0155","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.apsb.2024.06.003","article-title":"I n situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.114168_bb0160","series-title":"History of Hemostasis in Neurosurgery","author":"Paulo","year":"2018"},{"key":"10.1016\/j.jconrel.2025.114168_bb0165","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00701-013-1767-0","article-title":"The efficacy and safety of chitosan dextran gel in a burr hole neurosurgical sheep model","volume":"155","author":"Rajiv","year":"2013","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.jconrel.2025.114168_bb0170","article-title":"Gel\/hydrogel-based in situ biomaterial platforms for cancer postoperative treatment and recovery","volume":"3","author":"Feng","year":"2023","journal-title":"Exploration (Beijing)"},{"key":"10.1016\/j.jconrel.2025.114168_bb0175","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00701-018-3663-0","article-title":"Intracranial foreign material granulomas after cranial surgery","volume":"160","author":"Al-Afif","year":"2018","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.jconrel.2025.114168_bb0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-0031-1284394","article-title":"Massive swelling of Surgicel(R) Fibrillar hemostat after spinal surgery. Case report and a review of the literature","volume":"54","author":"Menovsky","year":"2011","journal-title":"Minim. Invasive Neurosurg."},{"key":"10.1016\/j.jconrel.2025.114168_bb0185","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10143-021-01684-1","article-title":"Topical hemostatic agents in neurosurgery, a comprehensive review: 15 years update","volume":"45","author":"Schonauer","year":"2022","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.jconrel.2025.114168_bb0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.otc.2016.02.003","article-title":"Hemostasis in Skull Base Surgery","volume":"49","author":"Alobaid","year":"2016","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2025.114168_bb0195","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0268-960X(91)90015-5","article-title":"Fibrin glue","volume":"5","author":"Brennan","year":"1991","journal-title":"Blood Rev."},{"key":"10.1016\/j.jconrel.2025.114168_bb0200","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1097\/CM9.0000000000002413","article-title":"A multicenter, prospective, randomized clinical study to evaluate the efficacy and safety of fibrin sealant as an adjunct to sutured dural repair","volume":"135","author":"Yu","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.jconrel.2025.114168_bb0205","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2165\/11207700-000000000-00000","article-title":"Fibrin sealant (evicel(R) [quixil(R)\/crosseal]): a review of its use as supportive treatment for haemostasis in surgery","volume":"71","author":"Dhillon","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.114168_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2010.06.025","article-title":"Fibrin glue as a drug delivery system","volume":"148","author":"Spicer","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114168_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0220","article-title":"In situ formed fibrin scaffold with cyclophosphamide to synergize with immune checkpoint blockade for inhibition of cancer recurrence after surgery","volume":"30","author":"Zhang","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.114168_bb0225","doi-asserted-by":"crossref","first-page":"9486","DOI":"10.1016\/j.biomaterials.2013.08.077","article-title":"The independent roles of mechanical, structural and adhesion characteristics of 3D hydrogels on the regulation of cancer invasion and dissemination","volume":"34","author":"Beck","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114168_bb0230","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1158\/0008-5472.CAN-08-4859","article-title":"The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells","volume":"69","author":"Ulrich","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114168_bb0235","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.1016\/j.biomaterials.2014.07.003","article-title":"A composite hydrogel platform for the dissection of tumor cell migration at tissue interfaces","volume":"35","author":"Rape","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114168_bb0240","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.1038\/ncomms9129","article-title":"A synthetic hydrogel for the high-throughput study of cell-ECM interactions","volume":"6","author":"Rape","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114168_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113951","article-title":"Rationally designed drug delivery systems for the local treatment of resected glioblastoma","volume":"177","author":"Bastiancich","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114168_bb0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.biomaterials.2017.05.007","article-title":"PNIPAAm-co-Jeffamine((R)) (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells","volume":"143","author":"Heffernan","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114168_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122052","article-title":"Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors","volume":"295","author":"Chao","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114168_bb0260","doi-asserted-by":"crossref","first-page":"15911","DOI":"10.1074\/jbc.M300463200","article-title":"Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha","volume":"278","author":"Yuan","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.114168_bb0265","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.114168_bb0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2016.05.016","article-title":"Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma","volume":"378","author":"Lang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.114168_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116620","article-title":"PX-478 induces apoptosis in acute myeloid leukemia under hypoxia by inhibiting the PI3K\/AKT\/mTOR pathway through downregulation of GBE1","volume":"230","author":"Liu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0280","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/ijc.23807","article-title":"PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells","volume":"123","author":"Palayoor","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114168_bb0285","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12885-021-08186-9","article-title":"Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines","volume":"21","author":"Parczyk","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2025.114168_bb0290","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/jgh.14110","article-title":"Notch signaling pathway regulates cell cycle in proliferating hepatocytes involved in liver regeneration","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0295","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2025.114168_bb0300","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0305","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2025.114168_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114168_bb0315","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-022-32091-9","article-title":"Cancer immune therapy using engineered \u2018tail-flipping\u2019 nanoliposomes targeting alternatively activated macrophages","volume":"13","author":"Kuninty","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114168_bb0320","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2176\/nmc.tn.2014-0024","article-title":"Modified hemostatic technique using microfibrillar collagen hemostat in endoscopic endonasal transsphenoidal surgery: technical note","volume":"54","author":"Fujimoto","year":"2014","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"10.1016\/j.jconrel.2025.114168_bb0325","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5603\/PJNNS.a2022.0074","article-title":"Haemostatic technique in malignant gliomas","volume":"56","author":"Dobran","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jconrel.2025.114168_bb0330","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00701-021-05067-9","article-title":"Reducing complication rates for repeat craniotomies in glioma patients: a single-surgeon experience and comparison with the literature","volume":"164","author":"Morshed","year":"2022","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.jconrel.2025.114168_bb0335","article-title":"Engineering a naturally derived hemostatic sealant for sealing internal organs","volume":"13","author":"Baghdasarian","year":"2022","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.jconrel.2025.114168_bb0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijpharm.2006.07.043","article-title":"Platelet adsorption and hemolytic properties of liquid crystal\/composite polymers","volume":"327","author":"Shih","year":"2006","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925007801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925007801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:08:37Z","timestamp":1780477717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925007801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":68,"alternative-id":["S0168365925007801"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114168","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In situ formed chemo-immunotherapeutic hydrogel for suppression of postoperative glioma recurrence and intraoperative hemostasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114168"}}